Sign in or create an account to add this stock to your watchlist.
About Madrigal Pharmaceuticals (NASDAQ:MDGL)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263
Debt
Debt-to-Equity RatioN/A
Current Ratio29.12
Quick Ratio29.12
Price-To-Earnings
Trailing P/E Ratio-47.76
Forward P/E Ratio-48.92
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$12.43 per share
Price / Book9.76
Profitability
EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-26.52%
Return on Assets-24.88%
Miscellaneous
Employees8
Outstanding Shares14,250,000
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.33. View Madrigal Pharmaceuticals' Earnings History.
What price target have analysts set for MDGL?
7 brokerages have issued 12-month price targets for Madrigal Pharmaceuticals' shares. Their forecasts range from $125.00 to $210.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $164.50 in the next year. View Analyst Ratings for Madrigal Pharmaceuticals.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC) and Array Biopharma (ARRY).
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
News stories about MDGL stock have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of 0.27 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (2.28%), BlackRock Inc. (2.24%), Victory Capital Management Inc. (1.42%), Citadel Advisors LLC (1.34%), Millennium Management LLC (0.65%) and Northern Trust Corp (0.52%). View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which major investors are selling Madrigal Pharmaceuticals stock?
MDGL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Rock Springs Capital Management LP, Victory Capital Management Inc., D.A. Davidson & CO. and Caxton Corp. View Insider Buying and Selling for Madrigal Pharmaceuticals.
Which major investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Artal Group S.A., UBS Group AG, Nexthera Capital LP, JPMorgan Chase & Co., Barclays PLC and Eventide Asset Management LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $121.31.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $1.74 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Madrigal Pharmaceuticals in the last 12 months. Their average twelve-month price target is $164.50, suggesting that the stock has a possible upside of 35.60%. The high price target for MDGL is $210.00 and the low price target for MDGL is $125.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $164.50 | $164.50 | $166.50 | $63.3333 |
| Price Target Upside: | 35.60% upside | 42.49% upside | 31.07% upside | 33.28% upside |
Madrigal Pharmaceuticals (NASDAQ:MDGL) Consensus Price Target History
Madrigal Pharmaceuticals (NASDAQ:MDGL) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Madrigal Pharmaceuticals (NASDAQ:MDGL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 56.70%
Institutional Ownership Percentage: 45.56%
Madrigal Pharmaceuticals (NASDAQ MDGL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/23/2017 | Richard S Levy | Director | Buy | 2,000 | $16.12 | $32,240.00 | 7,200 |  |
| 8/22/2017 | Richard S Levy | Director | Buy | 3,550 | $16.12 | $57,226.00 | 3,640 | |
| 8/21/2017 | Richard S Levy | Director | Buy | 3,550 | $15.88 | $56,374.00 | 900 | |
| 12/14/2015 | Keith R Gollust | Director | Sell | 600,000 | $0.35 | $210,000.00 | 401,764 | |
| 12/9/2015 | Keith R Gollust | Director | Sell | 745,892 | $0.38 | $283,438.96 | 401,764 | |
| 12/8/2015 | Bruce Kovner | Director | Sell | 1,523,346 | $0.37 | $563,638.02 | 3,092,677 | |
| 12/3/2015 | Bruce Kovner | Director | Sell | 1,430,753 | $0.43 | $615,223.79 | 3,092,677 | |
| 11/30/2015 | Bruce Kovner | Director | Sell | 3,078,820 | $0.48 | $1,477,833.60 | 3,092,677 | |
| 11/24/2015 | Bruce Kovner | Director | Sell | 1,173,582 | $0.44 | $516,376.08 | 3,092,677 | |
| 11/20/2015 | Bruce Kovner | Director | Sell | 1,513,088 | $0.49 | $741,413.12 | 3,092,677 | |
| 11/17/2015 | Bruce Kovner | Director | Sell | 1,223,936 | $0.43 | $526,292.48 | 3,092,677 | |
| 11/12/2015 | Bruce Kovner | Director | Sell | 5,436,673 | $0.55 | $2,990,170.15 | 3,092,677 | |
| 11/10/2015 | Keith R Gollust | Director | Sell | 188,322 | $0.55 | $103,577.10 | 401,764 | |
| 4/6/2015 | Robert N Wilson | Director | Buy | 50,000 | $1.75 | $87,500.00 | | |
| 9/30/2014 | Bruce Kovner | Director | Buy | 300,000 | $3.08 | $924,000.00 | | |
| 4/11/2014 | Bruce Kovner | Director | Buy | 1,250,000 | $4.01 | $5,012,500.00 | 3,048,666 | |
| 11/13/2013 | Bruce Kovner | Director | Buy | 5,000,000 | $3.75 | $18,750,000.00 | 6,130,330 | |
| 11/13/2013 | Safi Bahcall | CEO | Buy | 20,000 | $3.75 | $75,000.00 | 2,053,135 | |
| 6/28/2013 | Safi R Bahcall | CEO | Buy | 10,000 | $5.03 | $50,300.00 | | |
| 6/27/2013 | Bruce Kovner | Director | Buy | 150,000 | $4.71 | $706,500.00 | | |
| 6/26/2013 | Bruce Kovner | Director | Buy | 500,000 | $4.53 | $2,265,000.00 | | |
| 6/21/2013 | Bruce Kovner | Director | Buy | 250,000 | $4.39 | $1,097,500.00 | | |
| 6/21/2013 | Safi R Bahcall | CEO | Buy | 20,000 | $4.12 | $82,400.00 | | |
| 6/18/2013 | Bruce Kovner | Director | Buy | 200,000 | $4.00 | $800,000.00 | | |
| 6/14/2013 | Safi R Bahcall | CEO | Buy | 10,000 | $4.06 | $40,600.00 | | |
| 6/6/2013 | Bruce Kovner | Director | Buy | 2,000,000 | $4.64 | $9,280,000.00 | | |
| 6/6/2013 | Safi R Bahcall | CEO | Buy | 10,000 | $4.04 | $40,400.00 | | |
| 6/5/2013 | Vojo Vukovic | SVP | Buy | 10,000 | $4.58 | $45,800.00 | | |
| 6/4/2013 | Robert N Wilson | Director | Buy | 10,000 | $5.00 | $50,000.00 | | |
| 11/14/2012 | Bruce Kovner | Director | Buy | 37,700 | $6.91 | $260,507.00 | | |
| 11/12/2012 | Safi R Bahcall | CEO | Buy | 10,000 | $7.12 | $71,200.00 | | |
(Data available from 1/1/2013 forward)
Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Madrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 19 at 1:35 AM |
 | Madrigal Pharmaceuticals (MDGL) Shares March Higher, Can It Continue?
www.zacks.com - May 16 at 5:11 PM |
| Analysts Expect Madrigal Pharmaceuticals (MDGL) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - May 11 at 1:20 PM |
| Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to "Buy"
www.americanbankingnews.com - May 11 at 12:49 PM |
| Analysts Issue Forecasts for Madrigal Pharmaceuticals' Q2 2018 Earnings (MDGL)
www.americanbankingnews.com - May 11 at 8:35 AM |
| Madrigal Pharmaceuticals (MDGL) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 9:53 PM |
| Madrigal Pharmaceuticals' (MDGL) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 10 at 9:37 PM |
| Madrigal Pharmaceuticals (MDGL) Given a $130.00 Price Target at Oppenheimer
www.americanbankingnews.com - May 9 at 12:08 PM |
 | Madrigal: 1Q Earnings Snapshot
www.cnbc.com - May 8 at 5:11 PM |
 | Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
finance.yahoo.com - May 8 at 8:44 AM |
| -$0.75 Earnings Per Share Expected for Madrigal Pharmaceuticals (MDGL) This Quarter
www.americanbankingnews.com - April 24 at 3:20 AM |
| Madrigal Pharmaceuticals (MDGL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 24 at 1:30 AM |
| Oppenheimer Weighs in on Madrigal Pharmaceuticals' Q1 2018 Earnings (MDGL)
www.americanbankingnews.com - April 19 at 6:50 AM |
 | UPDATE: Oppenheimer Starts Madrigal Pharmaceuticals (MDGL) at Perform
www.streetinsider.com - April 18 at 5:22 PM |
| Madrigal Pharmaceuticals (MDGL) Now Covered by Oppenheimer
www.americanbankingnews.com - April 16 at 6:30 PM |
| Madrigal Pharmaceuticals Inc (MDGL) Short Interest Up 50.0% in March
www.americanbankingnews.com - April 14 at 2:27 AM |
| Cowen Reaffirms "Buy" Rating for Madrigal Pharmaceuticals (MDGL)
www.americanbankingnews.com - April 13 at 1:35 PM |
 | Active-Investors: Wired News - BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients
www.finanznachrichten.de - April 12 at 9:21 AM |
| Wired News – BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients
finance.yahoo.com - April 12 at 9:21 AM |
| Blog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome Treatment
finance.yahoo.com - April 11 at 9:07 AM |
| Madrigal Pharmaceuticals Inc (MDGL) Expected to Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 7 at 5:21 AM |
| Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 4 at 8:47 AM |
| Madrigal Pharmaceuticals (MDGL) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM |
| Madrigal Pharmaceuticals Inc (MDGL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 30 at 1:32 AM |
| Zacks Investment Research Upgrades Madrigal Pharmaceuticals (MDGL) to Buy
www.americanbankingnews.com - March 29 at 6:54 PM |
| Madrigal Pharmaceuticals (MDGL) PT Raised to $156.00
www.americanbankingnews.com - March 26 at 3:13 PM |
| Madrigal Pharmaceuticals (MDGL) Coverage Initiated at Goldman Sachs
www.americanbankingnews.com - March 23 at 6:50 PM |
| Goldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol Treatments
finance.yahoo.com - March 23 at 5:15 PM |
 | Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session - Nasdaq
www.nasdaq.com - March 21 at 9:37 AM |
| Madrigal Pharmaceuticals (MDGL) & Raptor Pharmaceutical (RPTP) Critical Comparison
www.americanbankingnews.com - March 18 at 11:30 AM |
| Roth Capital Reiterates Buy on Madrigal Pharma (MDGL) Following 4Q and Clinical Confusion - StreetInsider.com
www.streetinsider.com - March 18 at 8:42 AM |
| Madrigal Pharmaceuticals (MDGL) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 16 at 11:00 PM |
 | Madrigal Pharmaceuticals (MDGL) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 5:41 PM |
| Madrigal Pharmaceuticals (MDGL) Releases Earnings Results
www.americanbankingnews.com - March 14 at 9:43 AM |
 | BRIEF-Madrigal Pharmaceuticals Qtrly Loss Per Share $0.67
www.reuters.com - March 13 at 6:57 PM |
| Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196
finance.yahoo.com - March 13 at 8:55 AM |
| Sectoral Asset Management Inc Takes $3.38 Million Position in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 6 at 2:10 PM |
| Madrigal Pharmaceuticals Inc (MDGL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM |
| -$0.68 Earnings Per Share Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter
www.americanbankingnews.com - March 4 at 1:08 AM |
| Bogle Investment Management L P DE Buys New Stake in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 3 at 4:52 AM |
| Hudson Bay Capital Management LP Takes $2.75 Million Position in Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - March 1 at 12:03 PM |
| Madrigal Pharmaceuticals Inc (MDGL) Holdings Boosted by Ascend Capital LLC
www.americanbankingnews.com - March 1 at 4:41 AM |
| Madrigal Pharmaceuticals (MDGL) Coverage Initiated by Analysts at Cowen
www.americanbankingnews.com - March 1 at 12:30 AM |
| EAM Investors LLC Acquires Shares of 57,960 Madrigal Pharmaceuticals Inc (MDGL)
www.americanbankingnews.com - February 27 at 3:00 PM |
| Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
www.zacks.com - February 26 at 5:26 PM |
| 3 Top Biotech Stocks to Buy in February
finance.yahoo.com - February 26 at 8:41 AM |
| Zacks: Brokerages Expect Madrigal Pharmaceuticals Inc (MDGL) Will Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - February 15 at 1:24 PM |
| Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00
www.americanbankingnews.com - February 9 at 10:36 PM |
| Here’s What’s Moving Teva Pharmaceutical Industries And Madrigal Pharmaceuticals
finance.yahoo.com - February 9 at 9:39 AM |
| Madrigal Pharmaceuticals' (MDGL) Outperform Rating Reiterated at Evercore ISI
www.americanbankingnews.com - February 8 at 11:18 AM |
Madrigal Pharmaceuticals (NASDAQ:MDGL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Income Statement, Balance Sheet and Cash Flow Statement
Madrigal Pharmaceuticals (NASDAQ MDGL) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
